Keyword: Teva Pharmaceutical
Following an EpiPen generic launch by Teva, Novartis' Sandoz has released its launch plans for epinephrine alternative Symjepi.
Citing Mylan's EpiPen, two senators introduced a bill cracking down on drug misclassifications that cost Medicaid millions in underpaid rebates.
Bristol-Myers Squibb tried and failed to escape a lawsuit claiming it miscalculated average drug prices to underpay Medicaid rebates for years.
A judge ruled that Teva must face a lawsuit alleging employment discrimination in September, and now jurors ordered the company to pay $6.3 million.
All eyes are on Roche as the first biosimilar rival to big-selling lymphoma blockbuster Rituxan won FDA approval.
Philadelphia's city council is considering legislation to regulate pharma reps including prohibiting any gifts to healthcare providers and staff.
Mylan has found a valsartan API it made in India contains impurities, leading it and customer Teva to recall more than 60 lots of products.
The FDA has handed Lilly’s Emgality a 'breakthrough' nod in cluster headaches. Lilly plans to file for approval in that use by the end of the year.
Generic competition is weighing on Cialis, but luckily for Lilly, several new drugs are on the upswing, including top performers Trulicity and Taltz.
After suffering an earlier rejection for its biosimilar to Roche's Rituxan, Sandoz has now decided to abandon the drug.